Trials / Unknown
UnknownNCT04977193
A Study to Evaluate the Safety and Efficacy of ly011 Cell Injection in the Treatment of Advanced Gastric Adenocarcinoma
to Evaluate the Safety and Efficacy of LY011 Cell Injection（Targeting CLDN 18.2 Chimeric Antigen Receptor T Cells） in the Treatment of Advanced Gastric Adenocarcinoma
- Status
- Unknown
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- Shanghai Longyao Biotechnology Inc., Ltd. · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Objective to evaluate the safety and efficacy of ly011 cell injection in the treatment of advanced gastric adenocarcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | LY011 | CAR-T |
Timeline
- Start date
- 2021-11-01
- Primary completion
- 2023-05-01
- Completion
- 2024-11-01
- First posted
- 2021-07-26
- Last updated
- 2021-07-26
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04977193. Inclusion in this directory is not an endorsement.